NEW! Global Partnering Campaign & Roadshow Preparation Entrepreneurial Education Series

2 Feb

By Caitlin Dolegowski, Marketing Manager, LSN

2023 is an important year for LSN’s Entrepreneurial Education programs. We have devised 16+ focused and very practical 1-hour classes that address genuine issues facing startups. At Digital RESI March Life Science Nation will be offering an educational track for the first time, consisting of 6 focused classes over 3 days and covering topics:

It All Starts with The Story

Tuesday, March 14, 11 AM EDT

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch, or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook.

First-Time CEOs: Avoiding Pitfalls

Tuesday, March 14, 12 PM EDT

This session will cover some of the most common pitfalls that catch first-time and serial entrepreneurs off guard. From false premise and being tentative to surrounding yourself with executives that do not have augmentative and complimentary skillsets, there are many things that can slow the growth of your early-stage life science entity. By learning how to avoid these issues and not run yourself over, your chances of making it to the market will increase greatly.

Tagline & Elevator Pitch

Wednesday, March 15, 11 AM EDT

Distilling your company identity into a 5–7-word tagline and then expanding upon that in a 5-7 sentence elevator pitch is one of the most fundamental business development skills that early-stage entrepreneurs must master when launching global partnering campaigns. Join us to learn how to develop a compelling tagline and convincing elevator pitch to grip the attention of your target investors and licensing partners.

Executive Summary & Tear Sheet

Wednesday, March 15, 12 PM EDT

This session will cover how to develop a compelling 2-page executive summary and 1-page tear sheet, two of the most important materials to have at the ready for interested investors and licensing partners. While the executive summary covers a deeper dive into your company’s history, product, and management team, the tear sheet can be used to synthesize all of the most important elements of your company in 5-10 minutes (ideal for partners looking to skim through a document).

Pitch Deck & The 10 Myths of Fundraising

Thursday, March 16, 11 AM EDT

The pitch deck is the final piece of marketing collateral (having previously established your tagline, elevator pitch, executive summary, and tear sheet) that can help cogently tell your company’s unique story and highlight its key value points. As the pitch deck is one of the most requested materials by investors and licensing partners, this session will also cover the 10 myths of fundraising to help elucidate some common misconceptions when launching global campaigns.

Strategies for Successful Partnering

Thursday, March 16, 12 PM EDT

Take a deep dive into your outreach campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow up message after that.

Additionally, this registration includes access to investor panels, pitch sessions and workshops live or recorded for $295. (No Partnering)


Digital RESI March 2023 Email Banner.(NEWtouse)

Digital RESI March Panel Line-up

2 Feb

By Love Chung, Investor Research Analyst, LSN


The Redefining Early Stage Investment (RESI) conference series returns this March 14-16 in a fully virtual format. Through a carefully curated agenda including Innovator’s Pitch Challenges, educational workshops, panels, and more, entrepreneurs will be able to connect with investors and strategic partners who best match their product and stage of development. The panels will continue to feature investors, industry experts, and seasoned entrepreneurs providing valuable insight to our conference attendees.

Digital RESI March will be bringing on investor panels (featuring investors representing groups such as Angels, Corporate Venture Capital, Family Offices) that entail key topics of life science such as Therapeutics, Chronic Disease Management, Impact Investing, Health Systems, and more. Click here to see the agenda of the upcoming conference. To save $200 on Digital RESI, make sure to complete the early bird registration by February 10th!


Digital RESI March 2023 Email Banner.(NEWtouse)

I Asked an AI Robot to Tell Me About Entrepreneurial Storytelling (I am not kidding)

2 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

I asked the Robot, Open AI, Chat GPT to write an article on why scientist entrepreneurs and fundraising CEOs need to get their stories straight and develop a compelling company narrative. Here is the very impressive result!

In today’s business world, it is not enough for scientist entrepreneurs and fundraising CEOs to simply have a great idea or product. In order to be successful, they must also have a clear and compelling narrative that effectively communicates the value of their work to potential investors and customers.

One of the key reasons that a strong narrative is so important is that it helps to differentiate a company or product from its competitors. In a crowded marketplace, it can be difficult to stand out and make a lasting impression on potential investors or customers. By having a clear and compelling story, a scientist entrepreneur or fundraising CEO can effectively communicate the unique value proposition of their product or idea, and why it is worth investing in.

Another important reason that a strong narrative is necessary is that it helps to build trust and credibility. When a scientist entrepreneur or fundraising CEO can clearly and effectively communicate the value of their work, it helps to instill confidence in potential investors and customers that the company or product is worth supporting. This is especially important when seeking funding or investment, as investors are more likely to put their money into a company or product that they believe in.

Finally, a strong narrative can also help to build a sense of community and engagement around a company or product. When people are able to connect with the story of a company or product, they are more likely to become invested in it and to want to support it. This can be especially beneficial for fundraising CEOs and scientist entrepreneurs, as it can help to generate interest and enthusiasm among potential investors and customers.

In conclusion, scientist entrepreneurs and fundraising CEOs need to get their story straight and develop a compelling narrative in order to effectively communicate the value of their work and stand out in a crowded marketplace. By doing so, they can build trust, credibility and a sense of community around their company or product and increase the chances of success.

Click on the podcast/class below to hear my take on the question above.

Hot Investor Mandate: Global Life Sciences Solutions Provider Seeks to Partner With and Invest in Early-Stage Companies Developing Diagnostics & Life Science Research Tools

2 Feb

A global leader in life sciences, diagnostics and applied chemical markets provides services, equipment, and support solutions to laboratories worldwide. The firm has an early stage partnership program that works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit to Agilent’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Bioproduction Instrumentation, Cell & Gene Therapy Tools, Cellular Engineering and Analysis, Genomics, Lab Data Analytics & Informatics, Molecular Diagnostics and Sample Preparation. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Investment Arm Branched Out of a Life Sciences Consulting Firm Seeks to Invest in Novel Therapeutics, Medtech, etc. Addressing Unmet Medical Need

2 Feb

A newly established venture capital firm headquartered in Western Europe is tied with a dedicated life sciences consulting firm with multiple offices throughout USA, Europe, and Asia. With the capability to leverage the experienced resources from the consulting firm, the firm is able to invest in and support in early-stage technologies with a derisked strategy. The firm has a pan-European focus and is sourcing globally within industry, start-up communities, and business accelerators, for high potential opportunities.

The firm is interested in proprietary, differentiated therapeutic products addressing high-unmet medical need and platform technologies supporting next-generation patient diagnosis, treatment and disease prevention. The interest areas also include genomics, AI, diagnostics, medical devices, rare diseases, next generation personalized medicine, and more. The firm is interested in early-stage opportunities – pre-clinical assets with a valid proof of concept, devices with a working prototype are all good fits in terms of stage of development.

The firm will look at each opportunity carefully, and is most interested in those with business potential with a 3-5 year runway to strategic partnerships, acquisition by large life science companies or an IPO. The firm will prefer to lead investments and will take a very active role in their portfolio companies, often being involved in the operations of these companies to support their growth and enabling research that generates important, proof-of-concept data.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: USA-Based Investment Firm With Ties to Major Insurance Provider Invests Up to $20M in Digital Health, Healthcare Services, and More

2 Feb

An investment firm based in the US looks to invest in healthcare companies of strategic interest to a major healthcare insurance company that the firm has ties with, while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices, and agnostic towards types of technologies and indication areas the technologies address.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Biotech Company in USA Seeks Pre-Clinical Therapeutic Assets in Immuno-Oncology and Autoimmune Diseases for Potential In-Licensing or Investment

2 Feb

A biotech company based in the USA has an active pipeline of therapeutic assets in immuno-oncology and autoimmune diseases. The firm has been seeking novel therapeutics opportunities that are synergistic with the firm’s existing pipeline for potential licensing, investment, and other partnership opportunities. The firm is most interested in opportunities based in US and Europe.

The firm is seeking therapeutic opportunities for potential licensing, investment, and other win-win partnership opportunities. The firm is open to novel targets and modalities; in terms of indication/disease area, the firm is only considering immuno-oncology and autoimmune diseases at this time. In terms of stage of development, the firm will primarily consider pre-clinical stage assets.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: